The 'Strong Buy' Dividend Aristocrats the Market Recommends Fail the Income Test

A tip dropped into your inbox this morning: grab three Dividend Aristocrats before their September ex-dividend dates and you'll get paid on time. The stocks are Walmart, Johnson & Johnson, and Chevron. Wall Street gives them "Strong Buy" consensus ratings, which apparently means the income is safe.

But "Strong Buy" is a price-rating label, not a dividend check. It tells you which way analysts think the stock moves, not whether the payout can survive a bad quarter, a falling commodity price, or a slow year. If you're building a portfolio that funds your life through cash flow — not through liquidation later — the first question isn't what the analyst consensus says. It's whether these three companies are actually paying you anything, whether the money comes from real earnings, and whether the dividend streak is as solid as the headline implies.

Walmart (WMT) — The yield that doesn't show up

Walmart's dividend yield is 0.65%. On a $10,000 investment, that's $65 a year, or about $5.40 a month. You'd be waiting until November of next year to see $100.

The stock trades at 39 times trailing earnings and 38.7 times forward earnings, with a market cap of $890 billion. The payout ratio is 16.9%, meaning Walmart retains virtually every dollar of profit and hands back only a sliver. That's why the dividend is safe — and also why it's barely worth calling income.

The income question here is practical. If you're holding Walmart for the dividend, you're subsidizing the price appreciation bet of someone else's portfolio with your own capital. The payout won't be cut — but it also won't help fund a retirement on any meaningful scale. The "Strong Buy" rating makes sense for a growth-minded investor tracking Walmart's scale and digital penetration. It tells you nothing useful about income.

Johnson & Johnson (JNJ) — Not actually a Dividend Aristocrat

Here's the detail most listicles skip. JNJ spun off its consumer-health business as Kenvue in May 2024. The 62-year dividend streak historically credited to Johnson & Johnson was carried over to Kenvue. The remaining pharmaceutical and med-tech company — the JNJ you can still buy — has 23 consecutive years of dividend growth.

The Dividend Aristocrat threshold is 25. JNJ is two years short.

The dividend profile doesn't change because of a technicality. JNJ still pays a quarterly dividend of $1.34 per share, yielding about 2.0%. The payout ratio sits at 60%, which is well within a sustainable range. Free cash flow over the trailing twelve months is $22.6 billion. Coverage is fine.

But the aristocrat label the competitor article leans on — the one that signals "this company has never missed a step in five decades" — doesn't apply to the entity that's currently trading. The streak lives at Kenvue, not at JNJ. If you bought the headline, you bought the wrong ticker's history.

The income itself is durable. JNJ trades at 29.6 times trailing earnings, which is a premium valuation, but forward earnings push that multiple down to 18.8. The stock has surged 24.8% year-to-date after spending most of 2024 and early 2025 under pressure from Stelara patent loss and litigation over talc. The price recovery has compressed the yield from where it was a year ago.

The dividend is safe, but the aristocrat framing is stale.

Chevron (CVX) — The payout ratio exceeds earnings

This is the one where the "Strong Buy" label breaks down under a basic income check.

Chevron's trailing-twelve-month payout ratio is 117.5%. The company is paying out more in dividends than it earned. That's not a typo — it's what happens when a massive one-time earnings spike distorts the denominator.

Chevron's Q2 2026 EPS was $6.06, compared to a typical quarter in the $1.50 to $2.00 range. The spike came from a combination of higher oil realizations, record production of 3.97 million barrels per day (18% above the prior year, partly from the Hess acquisition), expanded refining margins, and a $1.5 billion favorable timing effect from commodity price declines. Revenue hit $70 billion versus $44.8 billion a year earlier.

Even if you strip out the Q2 anomaly and normalize that quarter to last year's $1.77 EPS, the trailing-twelve-month earnings come to roughly $6.55. The annual dividend is $6.83 per share. The payout ratio still tops 100%.

The 3.67% yield looks attractive until you notice it's funded by borrowing against future earnings or tapping free cash flow that isn't recurring. Chevron's free cash flow over the trailing twelve months is $27 billion, which comfortably covers the dividend bill today. But free cash flow in oil is cyclical — it surges when commodity prices and production are both favorable, and it shrinks when either turns. A payout ratio above 100% in a normal-earnings environment means the dividend has no margin of safety from earnings. It runs on cash, and cash is what falls first when the cycle turns.

The stock has climbed 22% year-to-date, then dropped 5.5% over the last five trading sessions. The price is reflecting some of the earnings normalization. The dividend payment for this quarter lands on September 10.

What the competitor article gets wrong

The "Strong Buy" consensus rating is a Wall Street tool for directional price bets. It measures whether analysts think a stock will rise, fall, or stay flat over the next 12 months. It does not measure whether a dividend is covered, whether a streak is intact, or whether the yield is high enough to matter for an income portfolio.

All three of these stocks have real businesses and long histories. None of them is a broken company. But the framing — "three Strong Buy Aristocrats that will pay you in September" — conflates analyst price sentiment with income reliability. It's a category error that hurts the reader more than it helps.

Walmart pays almost nothing. Johnson & Johnson isn't technically an Aristocrat anymore. Chevron's dividend exceeds its earnings even after you forgive the one-time windfall. The "Strong Buy" label glues the narrative together, but the income engine underneath each name doesn't match the headline promise.

What to look at instead

If you're trying to collect income before September's ex-dividend dates, start with the yield that actually funds something. Then check the payout ratio against normal earnings — not the quarter that includes a $12 billion windfall or a favorable timing effect. Then verify the streak you're relying on actually belongs to the ticker you're buying, not to a company that was spun off 25 months ago.

Three of the 69 current Dividend Aristocrats with September ex-dates that pass those basic checks: Realty Income (which pays monthly and yields 5.1% on a safe balance sheet), Procter & Gamble (2.9% yield, 69 years of increases, payout ratio in the 50s), and Abbott Laboratories (2.6% yield, 53 years of growth, payout comfortably below 60%). These names don't carry "Strong Buy" consensus in every case, but their income mechanics are transparent.

The income investor's job isn't to chase analyst labels. It's to verify the cash-flow engine, size the yield against what you're trying to fund, and walk away from anything that asks you to trust a headline over the numbers.